Efficacy Of Sibutramine And Topiramate Combination In Weight Loss: Retrospective Cohort Study On Brazilian Adults

IntroductionObesity is a chronic, prevalent, multifactorial disease, stigmatized and linked to multiple long-term complications, which makes the treatment currently available below of the expectations from what is necessary to combat it. Because of this limitation, off-label medications for the treatment of obesity, such as topiramate, have been widely used, in association with on-label medications, such as sibutramine, in order to achieve more effective weight loss. ObjectiveCompare the effectiveness of the combination of sibutramine and topiramate with sibutramine monotherapy in weight loss in obese adults in regular follow-up. An effective weight loss is expected in the association group, due to complementary mechanisms of act, and antagonistic side effects of drugs, leading to greater weight loss and therapeutic adherence. Materials and MethodsRetrospective cohort study with analysis of 66 medical records, distributed equally between groups. A weight loss of [≥] 5% was considered as an effectiveness criterion. ResultsThe group treated with the association, after a mean follow-up period of 52 weeks, had a mean weight loss of 9.0%{+/-}8.2, against 5.3% {+/-} 4.7 for the monotherapy group (p= 0.011). In the analysis of subgroups by weight loss categories, patients treated with the combination had an odds ratio of 6,7, to achieve [≥]15% weight loss than the monotherapy group (OR=6.7, 95%CI=[1, 3; 33.7]). ConclusionA more effective weight loss was observed in the group treated with the combination of sibutramine and topiramate, when compared to the monotherapy group, after 52 weeks.